甲磺酸伊马替尼 T1621
品牌 | 厂商性质 | 产地 | 货期 |
---|---|---|---|
TargetMol | 生产商 | 美国 | 现货 |
性能特点
生化试剂,可用于动物细胞实验
规格 | CAS号 | 价格 | 操作 |
---|---|---|---|
1 mL | 220127-57-1 | ¥387.00 | 询底价 |
200 mg | 220127-57-1 | ¥417.00 | 询底价 |
500 mg | 220127-57-1 | ¥756.00 | 询底价 |
5 g | 220127-57-1 | ¥3,930.00 | 询底价 |
100 mg | 220127-57-1 | ¥298.00 | 询底价 |
Product Introduction
Bioactivity
英文名: Imatinib Mesylate
描述: Imatinib Mesylate (STI-571) 是一种酪氨酸激酶受体抑制剂,具有抗肿瘤活性,对 v-Abl、c-Kit 和 PDGFR 的 IC50 分别为 0.6 μM、0.1 μM 和 0.1 μM。
细胞实验: Cells were added to 96-well plates at a density of 20?000 cells/well for HMC-1 and 50?000 cells/well for M-07e. Experiments with M-07e were performed with the use of GM-CSF or SLF as a growth factor supplement. Experiments using HMC-1 were performed without growth factor supplementation. Proliferation at 48 hours was measured with an XTT-based assay [1].
动物实验: Heterozygous experimental TRAMP mice were obtained by breeding wild-type C57BL/6 male mice and heterozygous female TRAMP mice. MC-deficient C57BL/6-KitW-sh/W-sh mice were intercrossed over 12 generations with TRAMP mice to obtain MC-deficient KitWsh-TRAMP mice. Cromolyn (10 mg/kg dissolved in saline; Sigma Aldrich) or imatinib (50 mg/kg dissolved in saline) were administered intraperitoneally in TRAMP mice for 5 days/week. Treatments started at 8 or 16 weeks, as indicated in text and figures, and continued for the duration of the experiment. Mice were sacrificed at 25 weeks and their urogenital apparatus collected for IHC [4].
体外活性: Inhibition of Steel factor (SLF)-induced c-kit autophosphorylation by STI 571 was dose-dependent, with complete inhibition observed at both 10 and 1.0 μmol/L. Inhibition was also apparent at a dose of 0.5 μmol/L, although limited c-kit autophosphorylation still occurred. Complete inhibition of MAP kinase activation occurred at 10- and 1.0-μmol/L concentrations of STI 571. Partial inhibition was observed at a dose of 0.1 μmol/L, and no inhibition occurred at a dose of 0.01 μmol/L. Total MAP kinase expression was not altered by treatment with STI 571 [1]. Exposure of cells to 1 μM STI571 for 24 hours before lysis resulted in a reduction of cellular tyrosine phosphorylation in general and of TEL/ARG specifically [2]. Imatinib had a more similar effect on Bcr/Abl- and c-Kit–dependent proliferation, with an IC50 of 19 nM in R10(-) cells and 82 nM in MO7e cells growing in the presence of SCF (KL, Kit ligand), respectively [3].
体内活性: The treatment of imatinib significantly reduced the incidence of adenocarcinomas (47.1% vs. 76.9% of untreated TRAMP mice) but had no effect against NE tumors, which instead significantly increased in frequency (23.5% vs. 15.4% of untreated TRAMP mice) [4]. In the imatinib group, lung function was improved with a lower W/D ratio. Perivascular edema and neutrophil infiltration were ameliorated. The imatinib group demonstrated maintained expression of VEC, inhibition of pCrkL, and a significantly higher level of interleukin (IL)-10 [5].
存储条件: Powder: -20°C for 3 years | In solvent: -80°C for 1 year
溶解度: H2O : 59 mg/mL (100 mM)
DMSO : 50 mg/mL (84.79 mM)
关键字: PDGFR | inhibit | Bcr-Abl | STI 571 | STI571 | CD117 | c-Kit | Platelet-derived growth factor receptor | Inhibitor | ST1571 Mesylate | SCFR | ST 1571 Mesylate | Autophagy | Imatinib | Imatinib Mesylate
相关产品: BGG463 | Berbamine dihydrochloride | PP121 | Vodobatinib | Dasatinib monohydrate | Vamotinib | Adaphostin | CHMFL-ABL-121 | BCR-ABL-IN-8 | N-Desmethyl imatinib
相关库: Drug Repurposing Compound Library | FDA-Approved Kinase Inhibitor Library | Anti-Cancer Drug Library | Membrane Protein-targeted Compound Library | Kinase Inhibitor Library | Inhibitor Library | Anti-Cancer Clinical Compound Library | Anti-Cancer Approved Drug Library | Tyrosine Kinase Inhibitor Library | Anti-Cancer Active Compound Library
甲磺酸伊马替尼 T1621信息由TargetMol中国为您提供,如您想了解更多关于甲磺酸伊马替尼 T1621报价、型号、参数等信息,欢迎来电或留言咨询。
注:该产品未在中华人民共和国食品药品监督管理部门申请医疗器械注册和备案,不可用于临床诊断或治疗等相关用途